RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Rating of “Buy” by Analysts
RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has been assigned an average recommendation of “Buy” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have covered the stock in the […]
More Stories
Shoe Carnival (NASDAQ:SCVL) Cut to Sell at StockNews.com
StockNews.com lowered shares of Shoe Carnival (NASDAQ:SCVL – Free Report) from a hold rating to a sell rating in a...
Philip Mazzara Sells 2,513 Shares of Astera Labs, Inc. (NASDAQ:ALAB) Stock
Astera Labs, Inc. (NASDAQ:ALAB – Get Free Report) General Counsel Philip Mazzara sold 2,513 shares of the firm’s stock in...
Roman DBDR Tech Acquisition Enters Definitive Agreement with CompoSecure Holdings
Roman DBDR Tech Acquisition (OTCMKTS:DBDRU) recently disclosed its entry into a key agreement with CompoSecure Holdings, a move that signals...
QUALCOMM Incorporated (NASDAQ:QCOM) CAO Sells $202,120.00 in Stock
QUALCOMM Incorporated (NASDAQ:QCOM – Get Free Report) CAO Neil Martin sold 1,304 shares of the stock in a transaction on...
PriceSmart (NASDAQ:PSMT) Cut to “Hold” at StockNews.com
StockNews.com lowered shares of PriceSmart (NASDAQ:PSMT – Free Report) from a buy rating to a hold rating in a research...
Merchants Bancorp Enters Underwriting Agreement for Depositary Share Offering
On November 18, 2024, Merchants Bancorp (NASDAQ: MBIN) entered into an Underwriting Agreement with Morgan Stanley & Co. LLC, UBS...